 |
|
|
|
 |
|
|
|
| Article 1 to 6 out of 6 concerning Enzon Pharmaceuticals, Inc.
|
-
Santaris Pharma's HIF-1 alpha antagonist begins second phase 1 study against solid tumours and lymphoma
(11/06/2007)
Enzon Pharmaceuticals, Inc. has initiated a second clinical study of EZN-2968 to evaluate additional dosing schedule
Santaris Pharma A/S announced the initiation of an open-label, non-randomized Phase 1 study with its HIF-1 alpha antagonist (EZN-2968) licensed outside Europe in 2006 to Enzon Pharmaceuticals, Inc. USA. The study is designed to evaluate the safety, ...
-
Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON From Enzon Pharmaceuticals, Inc.
(08/29/2007)
Drug Royalty LP 2 (DRC) announced the purchase of 25% of Enzon Pharmaceuticals, Inc.'s (ENZN) worldwide royalty interest in PEG-INTRON for $92.5M. DRC will also provide a $15M milestone payment in 2012 should certain royalty recognition levels be ...
-
Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha Antagonist
(04/03/2007)
Study to examine safety and tolerability in solid tumors and lymphoma
Enzon Pharmaceuticals, Inc. announced that the first patient has been enrolled in its clinical study of the HIF-1 alpha antagonist (EZN-2968). The open-label, non-randomized study is designed to evaluate the safety, tolerability, and pharmacokinetics...
-
Affitech signs license agreement for single-chain antibody technology with Micromet
(03/30/2007)
Affitech AS announced that it has signed an agreement with Micromet AG for a non-exclusive worldwide sub-licensable research license to the joint patent estate of Micromet and Enzon Pharmaceuticals, Inc. in the field of single-chain antibodies ...
-
Enzon Returns Rights To Transplantation Product To Fresenius Biotech
(01/10/2006)
Enzon Pharmaceuticals, Inc. announced that it is returning its rights to ATG-Fresenius S to Fresenius Biotech GmbH, a subsidiary of the health care company Fresenius AG. ATG-Fresenius S is a polyclonal antibody preparation used for T-lymphocyte ...
-
Enzon annouces termination of agreements with Inex
(03/21/2005)
Enzon Pharmaceuticals, Inc. announced that it has entered into an agreement with INEX Pharmaceuticals Corporation to terminate the companies' partnership for the development and commercialization of INEX's proprietary oncology product, MARQIBOŽ ...
|
|
|
Top